Amgen "market outperform," target price reduced

11.05.07 - Friedman,Billings,Ramsey &Co

NEW YORK, May 11 (newratings.com) - Analysts at Friedman Billings reiterate their "market outperform" rating on Amgen Inc (AMGN). The target price has been reduced from $56 to $55.